News >

Radiofrequency Ablation Dwell Time Significantly Impacts Survival in HCC

Published: Wednesday, Sep 30, 2015

Riccardo Lencioni, MD

Riccardo Lencioni, MD

Overall survival (OS) was improved by more than 25 months when lyso-thermosensitive liposomal doxorubicin (LTLD; ThermoDox) was administered with optimized (≥45 minutes dwell time) radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC), according to a presentation by Riccardo Lencioni, MD, at the 2015 International Liver Cancer Association (ILCA) Annual Conference.1

References

  1. Lencioni R. OPTIMA Phase III Clinical Trial: Study Design and Protocols. Presented at: International Liver Cancer Association 9th Annual Conference; September 4-6; Paris, France.
  2. Abou-Alfa GK. Thermodox in HCC: Development Plan and Lessons Learned. Presented at: International Liver Cancer Association 9th Annual Conference; September 4-6; Paris, France.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x